Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy

NCT01465347 is registered in ClinicalTrials.gov with Diffusion Pharmaceuticals Inc as lead sponsor.

NCT NCT01465347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01465347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy
Lead sponsor
Diffusion Pharmaceuticals Inc
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2012
Completion date
February 29, 2016
Enrollment
59 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioblastoma, glioma